West Pharma Beats Q4 Estimates, Raises 2025 Guidance to $3.07B
West Pharmaceutical Services reported Q4 earnings EPS $1.96 beating estimates by $0.27 on revenue of $805 million, up 5%, and raised 2025 sales guidance to $3.06–$3.07 billion. GLP-1 elastomer products now represent 9% of sales, and analysts’ average target of $348 implies 26% upside.
1. Q4 Earnings Beat
West Pharmaceutical Services delivered EPS of $1.96 in Q4, beating analyst estimates by $0.27, while revenue rose 5% to $805 million, driven by strong demand for injectable drug components.
2. Guidance Raise
Management increased full-year 2025 sales guidance to $3.06–$3.07 billion, citing robust order bookings and expansion of higher-margin product lines including advanced polymer containers and delivery devices.
3. GLP-1 Elastomer Growth
Sales from GLP-1 elastomer components accounted for 9% of total revenue, reflecting rising adoption of injectable GLP-1 therapies and supporting margin expansion for the injectable segment.
4. Analyst Outlook
Analysts maintain a bullish stance with a $348 average price target implying 26% upside, and West Pharma holds a top-tier Smart Score of 10, backed by increased hedge fund activity and positive technical indicators.